PB2044: FINAL PATIENT-REPORTED OUTCOMES FROM A PHASE 2, RANDOMISED TRIAL EVALUATING THE SAFETY AND EFFICACY OF POZELIMAB AND CEMDISIRAN IN PATIENTS WITH PAROXYSMAL NOCTURNAL HAEMOGLOBINURIA
Christopher Hartford,
Quang P. Nguyen,
Steven Sherman,
Rodrigo Pavani,
Lisa Aurand,
Diana Rofail,
Richard Kelly
Affiliations
Christopher Hartford
1 Regeneron Pharmaceuticals, Inc., Tarrytown, United States
Quang P. Nguyen
1 Regeneron Pharmaceuticals, Inc., Tarrytown, United States
Steven Sherman
1 Regeneron Pharmaceuticals, Inc., Tarrytown, United States
Rodrigo Pavani
1 Regeneron Pharmaceuticals, Inc., Tarrytown, United States
Lisa Aurand
1 Regeneron Pharmaceuticals, Inc., Tarrytown, United States
Diana Rofail
1 Regeneron Pharmaceuticals, Inc., Tarrytown, United States
Richard Kelly
2 St James’s University Hospital, Leeds, United Kingdom
